Barclays’s ANI Pharmaceuticals ANIP Stock Holding History

Barclays’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-200	Closed	-$14K	–	6914
2019 Q1	$14K	Sell	200 -2,500	-93%	-$147K	﹤0.01%	6461
2018 Q4	$122K	Sell	2,700 -1,200	-31%	-$62.9K	﹤0.01%	4910
2018 Q3	$221K	Buy	3,900 +3,500	+875%	+$214K	﹤0.01%	4919
2018 Q2	$27K	Sell	400 -5,800	-94%	-$362K	﹤0.01%	6012
2018 Q1	$361K	Buy	+6,200	New	+$394K	﹤0.01%	4283
2017 Q3	–	Sell	-2,000	Closed	-$94K	–	6823
2017 Q2	$94K	Hold	2,000	–	–	﹤0.01%	4950
2017 Q1	$99K	Buy	+2,000	New	+$112K	﹤0.01%	4881
2014 Q1	–	Sell	-976	Closed	-$20K	–	7557
2013 Q4	$20K	Hold	976	–	–	﹤0.01%	6714
2013 Q3	$9K	Sell	976 -257	-21%	-$1.85K	﹤0.01%	6818
2013 Q2	$7K	Buy	+1,233	New	+$8.63K	﹤0.01%	7247

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's ANIP Position: Q2 2026 in Review

Barclays increased its ANI Pharmaceuticals (ANIP) stake by 77% in Q2 2026, buying an estimated $4.19M and bringing the position to 119,707 shares worth $9.91M. The position accounts for ﹤0.01% of the portfolio, ranked #1483.

Barclays first reported a position in ANIP in Q2 2013 and has held it in 53 quarters since. The position peaked at $12M in Q2 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Barclays held 119,707 shares of ANI Pharmaceuticals worth $9.91M as of Q2 2026.
Barclays bought 52,260 ANI Pharmaceuticals shares in Q2 2026, an estimated $4.19M.
ANI Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1483 holding.
Barclays first reported a position in ANI Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
Barclays's ANI Pharmaceuticals position peaked at $12M in Q2 2025.
307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.